Abstract
Although numerous chemotherapeutic agents have been evaluated for patients with advanced prostate cancer, none have demonstrated improved survival benefits. Here, in order to determine whether the efficacy of chemotherapy can be enhanced by changing the regimen, we evaluated the effect of the varied timing and dosage of chemotherapy in combination with androgen withdrawal on time to androgen-independent (AI) progression in the human androgen-dependent LNCaP tumour model. We first demonstrated the synergistic effect of mitoxantrone on induction of apoptosis in LNCaP cells maintained in the steroid hormone-depleted charcoal-stripped media (CSM) compared to those in the standard media. In addition, this synergy was most remarkable during the simultaneous treatment of LNCaP cells with mitoxantrone and CSM compared to the pre- or post-use of mitoxantrone with CSM. LNCaP tumour growth in athymic nude mice and their increase in serum PSA levels were significantly inhibited by the simultaneous injection of mitoxantrone with castration, compared to the administration of mitoxantrone 2 weeks before or after castration. The TUNEL staining revealed that apoptotic cell death was extensively induced in LNCaP tumours treated with simultaneous castration and mitoxantrone compared to tumours treated with the other schedules. Furthermore, nude mice bearing LNCaP tumours were injected with a total of 0.5 mg mitoxantrone divided into 2, 5 and 10 days, with the most significant therapeutic effect and delayed AI progression observed in mice given injection of mitoxantrone for 2 days. These findings suggest that this might be the optimal way to perform cytotoxic chemotherapy and androgen withdrawal simultaneously in patients with advanced prostate cancer and to administer chemotherapeutic agents at high dosage within short intervals. © 2001 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Denis L and Murphy GP (1993) Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer 72: 3888–3895
de Reijke TM, Keuppens FI, Whelan P, Kliment J, Robinson MR, Rea LA and Sylvester RJ and Members of the European Organization for Research in Cancer Therapy Genitourinary Group (1999) Orchiectomy and orchiectomy plus mitomycin C for metastatic prostate cancer in patients with poor prognosis: the final results of a European Organization for Research in Cancer Therapy Genitourinary Group trial. J Urol 162: 1658–1665
Gleave M, Tolcher A, Miyake H, Nelson C, Brown B, Beraldi E and Goldie J (1999) Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin Cancer Res 5: 2891–2898
Hudes GR, Nathan FE, Khater C, Greenberg R, Gomella L, Stern C and McAleer C (1995) Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer. Semin Oncol 22: 41–45
Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer EP and Vogelzang NJ (1999) Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 17: 2506–2513
Miyake H, Hara I, Fujisawa M, Eto H, Okada H, Arakawa S and Kamidono S (1996) Comparison of hormonal therapy and chemohormonal therapy in patients with newly diagnosed clinical stage D prostate cancer. Int J Urol 3: 472–477
Miyake H, Nelson C, Rennie PS and Gleave ME (2000a) Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res 60: 170–176
Miyake H, Nelson C, Rennie PS and Gleave ME (2000b) Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2, in prostate cancer xenograft models. Cancer Res 60: 2547–2554
Miyake H, Tolcher A and Gleave ME (2000c) Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides. J Natl Cancer Inst 92: 34–41
Oh WK and Kantoff PW (1998) Management of hormone refractory prostate cancer: current standards and future prospects. J Urol 160: 1220–1229
Tang DG and Porter AT (1997) Target to apoptosis: a hopeful weapon for prostate cancer. Prostate 32: 284–293
Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM and Murphy KC (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14: 1756–1762
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Miyake, H., Hara, S., Arakawa, S. et al. Optimal timing and dosage of chemotherapy as a combined treatment with androgen withdrawal in the human prostate LNCaP tumour model. Br J Cancer 84, 859–863 (2001). https://doi.org/10.1054/bjoc.2000.1686
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1686
Keywords
This article is cited by
-
Behandlungsoptimierung fortgeschrittener urologischer Malignome
Der Urologe (2007)